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Abstract 
The high concentrations of free fatty acids as a consequence of obesity and overweight have 
become risk factors for the development of different diseases including neurodegenerative 
ailments. Free fatty acids (FAs) are strongly related to inflammatory events, causing  cellular 
and tissue alterations in the brain, including cell death, deficits in neurogenesis and 
gliogenesis and cognitive decline. It has been reported that people with a high body mass 
index have a higher risk of suffering from Alzheimer's disease. Hormones such as estradiol 
not only have beneficial effects on brain tissue but also exert some adverse effects on 
peripheral tissues including the ovary and breast. For this reason, some studies have evaluated 
the protective effect of estrogen receptor (ER) agonists with more specific tissue activities, 
such as the neuroactive steroid tibolone. Activation of ERs positively affects the expression 
of pro-survival factors and cell signaling pathways, thus promoting cell survival. This review 
aims to discuss the relationship between lipotoxicity and the development of 
neurodegenerative diseases. We also elaborate on the cellular and molecular mechanisms 
involved in neuroprotection induced by estrogens. 
 




Obesity and consumption of high-fat diets significantly increase the levels of free fatty acids 
in plasma, as well as the susceptibility to chronic inflammatory processes (1). Overweight, as 
a consequence, represents a common pathophysiological basis for many pathologies 
including chronic degenerative diseases, and constitutes one of the most important public 
health problems nowadays (2). A diet rich in simple sugars and saturated fatty acids reduces 
the expression of brain-derived neurotrophic factor (BDNF), and low BDNF levels are 
associated with insulin resistance and metabolic syndrome (3). The fat ingested with food has 
a dual function in the body. First, the energetic function of ingested fat is associated with the 
regulation of gene expression that affects the metabolism of lipids, carbohydrates and 
proteins, as well as cell growth and differentiation (4). Second, fatty acids interact with the 
genome through different mechanisms that include: i) alteration of various transcription 
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hepatocyte nuclear factor 4 (HNF4), nuclear factor-kappa B (NF-κB) and sterol regulatory 
element-binding proteins (SREBPs); ii) regulation of enzymes such as cyclooxygenase, 
protein kinase C, superoxide dismutase and catalase, and iii) changes in the the structure of 
cell membrane, affecting G protein-coupled or tyrosine kinase receptors (5). 
 
Metabolic alterations modify the correct functioning of the central nervous system (CNS) by 
changing the neuronal and glial environment (6). Also, the progression of CNS diseases is a 
consequence of the occurrence of exacerbated inflammatory processes that lead to continuous 
and systematic deterioration of brain tissues (7). Recent studies have suggested that people 
with obesity are more prone to develop cognitive pathologies such as Alzheimer's disease 
(AD), among others (8), leading to the generation of a large number of inflammatory 
processes as a consequence of the excess of free fatty acids (9-11).  
 
Decades ago, it was possible to characterize the cellular components responsible for the 
regulation and control of inflammation in the nervous system (12). The glial component, 
mainly astrocytes and microglia, are the main cells responsible for the regulation of 
inflammation (13). Acute activation of glia modulates neuroinflammatory response in a 
protective manner. On the contrary, chronic glial activation promotes neurodegeneration via 
secretion of inflammatory factors involved in neuronal loss (14). The regulatory mechanism 
is an extremely complex process determined by the transduction of inflammatory-type signals 
mediated by cytokines and chemokines (15). Despite the large body of information about the 
inflammatory mechanisms, it is not yet completely clear how the regulation of inflammation 
is carried out and how it can be altered in pathological events (16). However, previous studies 
support the assertion that modulation of exacerbated inflammatory processes may hold a 
therapeutic potential for many diseases of the nervous system. Inflammation can be regulated 
through the elimination and detoxification of neurotransmitters such as glutamate, and 
intracellular messengers by the glial cells. These cells are able to regulate glutamate levels 
under physiological and pathological conditions, and contribute to oxidative stress reduction, 
synaptic homeostatic maintenance and the regulation of inflammatory signals  (17, 18). In 
this regard, neuroactive steroids could play a critical role in the regulation of inflammatory 
processes in a pathological context, mainly by affecting the immunomodulatory function of 
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mediators (cytokines and chemokines) produced by microglia and other glial cells that are 
involved in neuroinflammation and neurodegeneration (19).  
 
It is clear that the brain is a steroidogenic tissue (20), and a target of endogenous and 
exogenous steroids. It is noteworthy that neuroactive steroids are steroids that come from 
peripheral glands (i.e. steroid hormones), which have effects on nervous tissue, while 
neurosteroids are those directly synthesised in the nervous system. It has been identified that 
treatment with estradiol regulates the expression of endoplasmic reticulum stress proteins (11, 
21, 22), protects mitochondria (22-25)  and regulates the expression and activation of 
membrane estrogen receptors, in addition to reducing the activity of proapoptotic proteases 
such as calpain and caspase-3 in glial cells under different metabolic challenges (26). 
Although palmitic acid may induce toxicity in glial cells (27, 28) and estrogenic compounds 
attenuate PA-induced neuroinflammation (29-32), the signaling mechanisms involved in 
these estrogenic actions are not fully explored and deserve further studies. This review 
highlights the inflammatory processes evoked by free fatty acids in glial cells. We also 
discuss the mechanisms of action of neuroactive steroids in the regulation of inflammation in 
glial cells as well as the therapeutic options that attenuate degeneration in the nervous system 
caused by glial reactivity. 
 
2. Metabolism of fatty acids and cellular mechanisms during injury 
Fatty acids (FAs) are an essential source of energy and ATP for the maintenance of cellular 
functions (33). Excess FAs, glucose and other nutrients can be efficiently stored as adipose 
tissue (34). Triglycerides provide more than twice the energy in the form of ATP compared to 
carbohydrates or proteins (35) since their catabolism generates more reducing equivalents 
(FADH2 and NADH2) and acetyl-CoA during β-oxidation in the mitochondria. 
 
Fatty acids are fundamental for cellular functioning as they are used as energy sources 
through β-oxidation under strict enzymatic control at the mitochondrial and peroxisomal 
levels (36). It has been described that FAs can be cytotoxic when the regulation of their 
metabolism is not adequate, with characteristic physiopathological consequences such as the 
induction of damage in various organs (e.g liver) that can culminate in non-alcoholic fatty 
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At the pancreatic level, FA-associated toxicity may lead to dysfunction of β cells. At the 
cardiac level, it may lead to the loss of myocardial contractility with consequent heart failure, 
while it may act as a precursor of neuroinflammatory processes in the brain (38). 
 
Lipotoxicity is a phenomenon characterized by increased levels of FAs. Also, increased 
amounts of FAs can induce the activation of various metabolic pathways that cause the 
uncoupling of cellular metabolism, with the generation of signaling cascades related to the 
start of programmed cell death and finally cellular energetic failure (39). In obesity, excessive 
consumption of foods rich in carbohydrates and excessive release of FAs by adipose tissue 
exceed the storage limit and the capacity of oxidation in different tissues (40). In this regard, 
FAs are redirected to harmful non-oxidative metabolic pathways, which are linked with the 
intracellular accumulation of toxic metabolites such as ROS (41).  
 
The oxidation of FAs increases the proportion of acetyl coenzyme A/coenzyme A and 
NADH/NAD+ in mitochondria, which results in the inactivation of pyruvate dehydrogenase 
(42). Inactivation of this enzyme leads to the accumulation of citrate and subsequent 
inactivation of the enzyme phosphofructokinase. In turn, this latter inactivation leads to the 
accumulation of glucose-6-phosphate, which then stimulates the synthesis of glycogen and 
the inhibition of hexokinase, resulting in the inhibition of glucose uptake (43).  
 
A large amount of FAs available at the cellular level that is not used by cellular activity can 
negatively alter the process of β-oxidation and affect cell/energy balance. When this process 
is impaired, the FAs are metabolized by alternative routes and are degraded or incorporated 
into other molecules (44). FAs can have damaging cellular effects by increasing the activity 
of the serine palmitoyl transferase that catalyzes the condensation of palmitoyl coenzyme A 
and serine to form dihydrosphingosine. This is the first step for the de novo synthesis of 
ceramide, a molecule involved in the regulation of cellular processes such as cellular 
differentiation and proliferation, in addition to cellular apoptosis, through the expression of 
the antiapoptotic molecule Bcl2 (45). The accumulation of metabolites involved in the 
synthesis of ceramides, along with other catabolic products of FAs triggers a signaling 
network between the endoplasmic reticulum, the cell nucleus and the mitochondria. For 
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protein (IRE1), transcription activating factor 6 (ATF6) and protein kinases like the PKR of 
the endoplasmic reticulum (PERK) (46). The intracellular accumulation of palmitic acid and 
stearic acid causes the activation of apoptosis via IRE1 and PERK in humans with non-
alcoholic steatohepatitis (47). The mitochondria are the main cellular compartment affected 
by FAs, whereby the increase of mitochondrial β-oxidation, the induction of cytochrome 
P450 and leukocyte infiltration result in the generation of oxidative stress and nitrogenfree 
radicals (48). Several studies on obesity and non-alcoholic steatohepatitis in male patients 
have revealed an increase in the expression of metabolites derived from oxidative stress 
caused by the excess of FAs (49). Some of these metabolites include 4-nitrotyrosine, 
hydroxynonenal, substances reactive to thiobarbituric acid (lipoperoxidation markers) and 8-
hydroxydeoxyguanosine (a marker of DNA damage), among other biomarkers of oxidative 
stress (50).  
 
Several investigations have shown that toll-like receptors (TLR), which are responsible for 
transducing FA-induced signaling, recognize the pathogens and respond by activating the 
innate immune response (51, 52). In macrophage cultures of female C57BL/6 mice, lauric 
acid could activate TLR4 receptor and dimerize with TLR2 (53). TLR4 can also be activated 
by palmitic acid, thereby triggering the translocation to the nucleus of NF-κB and subsequent 
overexpression of the pro-inflammatory cytokines tumor necrosis factor-α (TNF-α) and IL-6 
(54). These cytokines, in turn, contribute to the inflammatory process associated with obesity 
(55) (Figure 1). 
 
Previous studies have reported an association between high-fat diets and cognitive decline 
in humans (56). In addition, a higher probability of suffering from dementia has been 
associated with the development of inflammatory processes and obesity (22). Sedentary 
lifestyle, lack of physical activity and unhealthy eating habits have been cataloged as 
determining factors in the development of neurodegenerative diseases due to the 
inflammatory response that is generated in the brain (57). Furthermore, these factors may 
influence the outcome of other types of injuries that alter brain function, such as traumatic 
brain injury (TBI), thereby producing alterations in the cerebral energy machinery that 
prevent tissue repair and delay the recovery of cerebral function (58). Indeed, obesity, 
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increases the consequences of TBI (59). This occurs due to the transient alteration of 
glucose demands and the presence of high concentrations of free FAs that is a characteristic 
of obese patients (60).  
 
Some studies have reported an increase in the levels of saturated FAs in post-mortem 
human brains with TBI (61, 62). In studies of male and female mice that underwent TBI, it 
was found that obesity increases the activation of glial cells (astrocytes and microglia), the 
expression of neuroinflammatory factors and the impairments of learning and memory 
processes (63). All these alterations suggest that obese people have a reduced ability of the 
injured brain to respond with neuroprotective and anti-inflammatory actions. Therefore, 
obesity can be a contributing factor triggering neuroinflammation (64). Also, it has been 
well established that estrogens play an essential role in the prevention of body weight gain 
(65). There is a strong relationship between the development of obesity, diabetes and the 
metabolic syndrome with a dramatic drop in the circulating levels of 17 β-estradiol (E2) in 
post-menopausal women (66). Treatment with E2 significantly reduces the risk of developing 
these pathologies (67) because the action of E2 on estrogen receptors (ERs) triggers the 
activation of intracellular signals that counteract the inflammatory process (68). However, 
these therapeutic benefits provided by E2 can be accompanied by negative side effects such 
as reproductive endocrine toxicity (69) and the development of breast cancer (70). Due to the 
above-mentioned side effects, administration of estrogen in post-menopausal women is not 
free from controversy and alternative compounds, such as tibolone, are being used in clinical 
practice (see section 5). 
 
3.   Lipotoxicity, glial cells, neurodegeneration and neuroinflammation  
The release and presence of a large amount of saturated FAs in the bloodstream can affect 
brain function. Development of inflammatory processes in the nervous system contributes is 
a decisive risk factor for neurodegenerative diseases. These changes in the cerebral 
environment contribute to the activation of microglia as a mechanism of defense and repair; 
however, the presence of exacerbated and prolonged processes can trigger a deregulation in 
microglial activation, which will stimulate additional release of inflammatory factors by these 
cells. This can culminate in the elevated levels of several pro-inflammatory cytokines and 
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many neurodegenerative disorders such as age-related macular degeneration, Alzheimer's 
disease (AD), multiple sclerosis, Parkinson's disease (PD), Huntington's disease and 
tauopathies (71).  
 
The increase in life expectancy in some countries is directly related to the increase in the 
prevalence of AD (72). AD is mainly associated with aging, with this being the main risk 
factor in the onset of this neurodegenerative pathology (73) but a higher risk has also been 
found in patients with obesity. Together with alterations in oxidative stress and mitochondrial 
dysfunction (74), the progression of AD is directly linked to alterations in local immune 
responses, characterized by inflammation and activation of astrocytes and microglia (75). 
Indeed, neuroinflammation is involved in multiple pathological mechanisms of AD and pro-
inflammatory mediators such as IL-1β, IL-6 and TNFα have been shown to be associated 
with the disease (76). 
 
Chronic inflammation in AD is a general observation (77), while oxidative stress precedes 
neuronal damage (78). Other inflammatory mediators such as IL-1β, transforming growth 
factor-β (TGF-β) and inducible cyclo-oxygenase (COX-2) have been found to be upregulated 
in AD (76). Most studies and experimental evidence indicate that a pro-inflammatory 
environment promotes the development of AD, while anti-inflammatory treatment decreases 
its progression (79, 80). 
Neuroinflammation may be neuroprotective at early stages but has chronic negative effects if 
the stimulus responsible for inflammation persists, causing over-activation of microglia and 
increased release of cytokines (81). For example, amyloid plaques are surrounded by glia that 
secrete pro-inflammatory molecules including TNF-α, IL-1β and MCP-1, which in turn 
increase neuronal sensitivity to free radicals and accelerate neurodegeneration (82). Another 
factor that favours neuroinflammation is inducible nitric oxide synthase (iNOS), which has 
been found to be increased in the AD brains (83). The effects of treatment with non-steroidal 
anti-inflammatory drugs (NSAIDs) (84) and estrogens on the inflammatory processes 
involved in different diseases have been widely reported. (85). Due to the low estrogen levels 
that have been found in obese patients with increased levels of free fatty acids, hormonal 
supplements have been used (33, 40) and this replacement therapy significantly decreased the 
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PD is another neurodegenerative disease affected by the neuroinflammatory processes 
activated by FAs, and is the second most common neurodegenerative disorder after AD. It 
affects 1-2% of the general population above 65 years of age (86). One of the markers of 
neurodegeneration in PD is the abnormal accumulation of α-synuclein protein in neurons, 
which triggers the activation of glial cells and the progression of inflammation (87). Reactive 
microglia have been observed in the substantia nigra of patients with PD, which suggests that 
this inflammatory process could aggravate neurodegeneration (88). Indeed, active microglia 
and, to a lesser extent, reactive astrocytes are associated with neuronal loss. This is due to the 
release of TNF-α, IL-1β and IL-6, prostaglandins (PGE2, PGD2), reactive oxygen species 
(ROS), and nitric oxide (NO) (89). However, analysis of neuronal loss in patients with PD 
demonstrates that it is a heterogeneous process since neurons containing neuromelanin are 
predominantly involved (90). This leads to an increase in the pro-inflammatory molecules 
TNF-α, IL-6 and NO that trigger neuroinflammatory processes. It is noteworthy that 
neuromelanin has a crucial role in microglial activation, which leads to a vicious circle of 
neuronal death (91). 
 
4. Estrogens and the brain 
Estrogens play a vital role in both male and female reproductive physiology, stimulating cell 
growth and differentiation in various tissues such as breast, uterus, vagina, ovary, testis, 
epididymis and prostate (92). It has been shown that estrogens are of great importance in 
cardiovascular physiology; for example, the risk of cardiovascular disease is lower in women 
than in men before menopause (93). After menopause, the levels of E2, the estrogen that 
predominates in the circulation before menopause, decreases to the level found in men of 
similar age and can sometimes be even lower (94). Estrogens are required for neuronal 
growth and differentiation and are known to affect cognitive and mood functions. In addition, 
estrogens can be useful in preventing or delaying the onset of degenerative diseases of the 
nervous system. Most actions of estrogens in the brain are thought to be mediated by 
activation of estrogen receptor alpha (ERα), estrogen receptor beta (ERβ) or GPER, a G 
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4.1 Role of estrogenic compounds in glial cell function and inflammation 
ERs are proteins belonging to the superfamily of nuclear receptors, which also include other 
receptors for steroid hormones, the vitamin D receptor, retinoids, thyroid hormone, and some 
orphan receptors. ERs were identified approximately 40 years ago when in 1962 the presence 
of estrogen-binding sites in different tissues of rats was described. Two isoforms are currently 
known, ERα and ERβ (95). The ERs present a diverse subcellular localization and can be 
detected in the cytoplasm (96), nucleus (97), mitochondria and endoplasmic reticulum (98). 
Both receptors (ERα and ERβ) have different functions according to the tissue where they 
exert their actions. The classical theory of action of steroid hormones states that the steroid 
receptor is activated by binding to the ligand (in this case E2), and acts as a transcription 
factor by binding to DNA and stimulating gene transcription. Because these nuclear receptors 
exert their actions in the nucleus, their mode of action is so called genomic (99). The 
transcription stimulated by the ER is regulated in a tissue-specific manner. However, in 
addition to its canonical response, estradiol can induce effects quickly and independently of 
genomic mechanisms (100). The non-genomic mode of action of estradiol (and in general for 
all steroid hormones) is a rapid process that does not require the synthesis of new proteins, 
and is mediated by receptors localized in the membrane (101). The rapid estrogenic action 
includes the regulation of ion fluxes, discharge of secretory vesicles and activation of protein 
kinases associated with the membrane (102). In 1967, the idea that estradiol could induce its 
cellular effects through non-genomic mechanisms was introduced, as evidenced by the 
increase in the production of cyclic AMP (cAMP) in vivo (103, 104). Subsequently, it was 
demonstrated that E2 increases the intracellular concentration of Ca2+ induced by glucose and 
cyclic GMP (cGMP) in beta cells of the pancreas (105).   
 
In the last decade, evidence has emerged about the role of G protein-coupled receptor for 
estrogen (GPER) in the metabolic regulation of the nervous system (106). The GPER is a 
receptor coupled to the G protein of 7 transmembrane domains, while its expression and 
distribution has been demonstrated in a wide variety of cells and tissues (107). The GPER is 
located in the plasma membrane but many investigations have identified it in other 
subcellular compartments, particularly in the endoplasmic reticulum and the Golgi apparatus 
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It has been shown that estradiol binds to the GPER and activates multiple signaling pathways 
(107). It is known that GPER exerts its effects through rapid non-genomic signaling and 
transcriptional activation (109, 110). The mechanisms of action of this receptor depend on the 
type of tissue as well as the abundance and expression of receptors. The rapid non-genomic 
signaling in response to E2 through GPER can activate multiple signaling pathways, 
including MAPK, PI3K, PKC, Ca2+ and adenylyl cyclase (111-113), demonstrating activation 
of some survival and metabolic downstream pathways. Depending on the cellular context, the 
GPER can mediate proliferative and survival responses (114). Although the mechanisms of 
action of the GPER are still unclear, it has been described that it is also a target of other 
molecules with estrogenic activity such as tamoxifen, which has been related to the regulation 
of functions in the central nervous system  (115).  
 
There is a key regulatory role of the estrogenic response in inflammatory processes (116, 
117).  In inflammatory in vitro and in vivo models, it has been shown that administration of 
estradiol and Selective Estrogen Receptor Modulators (SERMs) decreases the expression of 
the proinflammatory cytokines IL-1β, IL-10 and TNFα (118, 119). Raloxifene, another 
SERM, has also been shown to protect mitochondria in astrocytic cells exposed 
to glucose deprivation (120). On the other hand, administration of estradiol can 
modulate the mitogenic stimulation of B and T lymphocytes, and as a consequence, increase 
the production of immunoglobulins such as IgM. Indeed, epidemiological studies have 
shown that women of any age experience lower rates of infection and mortality associated 
with inflammatory processes compared to men (121).  
 
The relationship between the estrogenic response and inflammation is also associated with 
the differential activity of the estrogen receptor subtypes (122). For example, in patients 
with rheumatoid arthritis, a density analysis of ERα and ERβ in synoviocytes showed a 
greater presence of ERβ (121). The same trend is observed in patients with systemic lupus 
erythematosus, where T lymphocytes have a higher concentration of ERβ+ lymphocytes 
than ERα+ lymphocytes (1 22 ) .  In the case of the nervous system, inflammation can be 
triggered by conditions such as oxidative stress, endotoxins, mechanical damage and 
chronic neurodegenerative diseases (123). Inflammation can be acute or chronic and the 
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cellular components such as microglia and astrocytes (124-126). It has been shown that 
human astrocytes can secrete molecules associated with inflammation such as interleukins 
and chemotactic factors such as MCP-1, MIP-1α and inducible factor IP-10 (127). De 
Marinis et al. reported that astrocytes are actively involved in the secretion of pro-
inflammatory molecules IL-6 and INF-γ (116, 128, 129). Additionally, estradiol has the 
ability to decrease the secretion of these inflammatory molecules in an oxidative model 
mediated by H2O2 following stimulation with LPS, whose response is associated with the 
NF-κB pathway (130). This response is similar in astrocytes by reducing the release of 
proinflammatory molecules in metabolic dysfunction models (131), such as stimulation 
with palmitic acid (27) (Figure 3). 
 
Some neurosteroids such as DHEA modulate microglial activation and immune response in 
vitro (132). In in vivo experiments, neuroactive steroids inhibited TNF-α and INFγ in 
astrocytes and microglia (133). In contrast, progesterone (PROG) did not inhibit the immune 
responses of microglia (85) but prevented morphological changes associated with activated 
microglia phenotype (134). Additionally, other studies reported that PROG did not have anti-
inflammatory effects on mixed cultures of astrocytes and microglia but inhibited microglial 
proliferation in separate cultures (135). 
 
Both central and peripheral steroids participate in the activation and protection of the brain, in 
particular during the aging process and after an injury (136). The neuroprotective actions of 
steroids have been reported in several studies, in which it is shown that these compounds 
have a highly specific affinity to their nuclear receptors and mediate several protective 
functions, among which are the increase in the levels of anti-inflammatory factors, anti-
apoptotic factors, and decrease in the expression of inflammatory mediators (137). 
Pregnenolone and dehydroepiandrosterone are known to promote the survival and 
differentiation of neuronal cells grown from embryonic rat brain (138). In a similar way, 
estradiol, tamoxifen and raloxifene reduced the activation of microglia in male and female 
rats after peripheral inflammation induced by the administration of LPS. This latter effect was 
proposed to be mediated by a mechanism that may involve ER in microglia, thereby 
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The classical mechanism of action of steroid hormones in the brain is through interaction 
with their intracellular receptors (ERs, progesterone and androgen receptors) (140, 141). The 
expression of these receptors by glial cells allows them to partially mediate the action of 
estrogenic compounds in the brain (118). Indeed, the response induced by each receptor 
stimulats cell survival, differentiation and connectivity of neurons and glial cells in the brain, 
including the medulla (102). Also, neurosteroids play an important role in the development of 
the prenatal CNS, while regulating behavior and neuroendocrine signaling in the adult brain 
(142). Although many of the signaling pathways activated by estrogen are known, the anti-
inflammatory molecular mechanisms are not completely clear (143). 
 
Many of the neurodegenerative diseases are characterized by the development of brain 
inflammation as a consequence of injuries or metabolic damage (59). As mentioned above, 
inflammation in the nervous system can be triggered by conditions such as oxidative stress, 
endotoxins, cytokine secretion, mechanical injury and chronic neurodegenerative pathologies 
(12). This inflammation can be acute or chronic, and the cellular components of the nervous 
system such as microglia or astroglia can respond to estrogenic activity by modulating these 
inflammatory processes (126). 
 
Body weight increases in several conditions associated with hormonal decline. In women, 
estrogens favor the deposition of fat in some parts of the body; however, after menopause the 
fat subcellular localization changes, being more similar to men (144). The adipose tissue is 
capable of producing estrogens through the aromatization of androgens and an increase in the 
blood concentration of estrogens has been observed in men with obesity but this is not 
evident in women (145). It has been demonstrated that ERα is the main isoform that 
participates in the control of weight by estrogens and the absence of ERα produces 
hyperpalsia and hypertrophy of the adipocytes (146). 
 
Taking into account alterations in plasma estrogen levels, the increase in free saturated FAs 
and the infiltration of proinflammatory agents is presented as the ideal scenario for the 
development of neurodegenerative diseases. Estrogens play a fundamental role in the 
prevention of obesity (147). Studies in female mice showed a weight gain and hyperadiposity 
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estradiol reduced the development of this obese phenotype (148), demonstrating that these 
effects on the homeostasis of body weight are mediated mainly by the activation of ER (149). 
Humans or mice with mutations in the ER gene (ESR1) are obese (150). Likewise, estradiol 
therapy was found to have no effect in mice subjected to ER suppression (151). 
 
The estrogenic response associated with inflammatory processes has been found to have the 
ability to decrease the secretion of inflammatory molecules and reduce the production of 
ROS (152). In this regard, it was reported that this mechanism was associated with the 
response of ER through the activation of the inflammatory pathway NF-κB (153) (154), as 
well as the expression and modification of some proteins such as neuroglobin (24). For 
instance, neuroglobin is a monomeric globin protein of about 150 amino acids (155) that has 
the capacity to transport and store oxygen owing to the heme group it contains (156). 
Hormonal regulation of neuroglobin and protective mechanisms are discussed in more details 
below.  
 
4.2 Signaling mechanisms associated with estrogen-induced neuroprotection  
Neuroglobin has been studied in different models of damage such as focal cerebral ischemia, 
β-amyloid peptide-mediated toxicity, anoxia, and glucose and oxygen deprivation (157). The 
presence of neuroglobin, once thought to be expressed only in neurons, has recently been 
discovered in glial cells. Although the neuroprotective effects of neuroglobin have been 
identified in these models, its molecular mechanisms of action are not yet well established 
(158) (159). Several investigations have found that estrogens and androgens can regulate the 
expression of neuroglobin, hence the modulation of this protein by estrogenic activity (160) 
could be partly responsible for the protective effects of estradiol in models of oxidative stress 
(157). 
 
Despite its broad spectrum of protective effects, the molecular mechanisms of action of 
neuroglobin are poorly understood (161). It has recently been shown that neuroglobin is a 
hormone-inducible protein (162). Neuroglobin has the potential to be a hypoxia signaling 
molecule, free radical scavenger or NADH oxidase capable of supporting anaerobic glycolysis 
(161). Several lines of evidence regarding neuroglobin’s tendency to auto-oxidate, its low 
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could play different roles ranging from oxygen storage to facilitating its diffusion (163, 164). 
Additionally, photoactivation experiments of NADH/FMN that induce a reducing state in 
neuroglobin suggest that this protein participates in the elimination of oxygen radicals, 
mainly through reacting with NO to form a peroxynitrite radical that converts to the more 
stable form  nitrite (165). The previous mechanism suggests a protective role for neuroglobin 
in the regulation of highly reactive species such as peroxynitrite  (166). Under conditions of 
normoxia, neuroglobin is bound to oxygen while under hypoxic conditions, according to 
deoxygenation experiments, neuroglobin adopts a hexacoordinated structure (163, 167). This 
structure can be a signal indicating the low levels of oxygen in the cellular environment, 
triggering events to protect the cell from death (116). Therefore, overexpression of 
neuroglobin could increase survival in conditions of low oxygen levels. Additionally, 
hypoxia produces a pH decrease and this condition also favors the hexacoordinated 
conformation of neuroglobin (167, 168). Interestingly, neuroglobin is a hormone-regulated 
protein (24, 32, 130, 160), suggesting that estrogenic compounds (estradiol and tibolone) or 
androgens (testosterone) can modulate its expression. The protective actions of tibolone are 
discussed in the next section.   
 
5. Tibolone: a neuroactive steroid and regulator of estrogenic activity 
The family of drugs with selective tissue-specific estrogenic activity is called STEAR (169). 
The most representative molecule of this family of drugs is tibolone (170). Tibolone is 
considered as a synthetic steroid with estrogenic, progestogenic and androgenic activity 
(171). Tibolone is prescribed for the treatment of climacteric symptoms in post-menopausal 
women (172). 
 
Tibolone has a 3-keto-δ5-10 configuration, a 7α-methyl substituent, and a 17α-ethynyl group 
that per se cannot explain its combined effects in different tissues like vagina, bones and 
brain (170). Additionally, this compound mimics the activity of estradiol through neither an 
aromatic ring nor the 3-OH substituent, which is necessary to act as an agonist of ER (77). Its 
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Tibolone is rapidly metabolized in the body to three different metabolites: a) 3α- and b) 3β-
OH-tibolone, metabolized by the enzymes 3α/β hydroxy-steroid dehydrogenase - HSD, 
respectively, and c) δ4-tibolone also called δ4-isomer, metabolized by the enzyme 3β-HSD-
isomerase (77), which explain the combined activity of tibolone. Specifically, clinical 
evidence has indicated that 3α- and 3β-OH-tibolone metabolites are responsible for the 
estrogenic activity, while δ4-tibolone is associated with the progestogenic and androgenic 
activity, determined by its ability to interact with androgen and progesterone receptors (169). 
Similar to one of the predominant forms of estrogen (estradiol), tibolone is metabolized to 
weak sulfated estrogenic forms that serve as a substrate of sulphatase-type enzymes for the 
permanent production of estrogenic metabolites in different tissues (173). 
 
Tibolone and its metabolites have different types of activities (progestogenic, androgenic and 
estrogenic) in different tissue types (liver, bone, breast tissue and brain, among others), 
depending on the selective modulation of the receptors with which they interact (174). In 
studies where an estrogenic compound (E2) was used in models of cerebral ischemia in mice, 
it was demonstrated that the activation of the ERβ is neuroprotective against the damage 
(175). Similar to this work, a study investigated the neuroprotective effects of estradiol and 
an ERα ligand using a model of multiple sclerosis. In the absence of anti-inflammatory 
effects, it was found that treatments based on the ERβ would potentially allow the 
development of neuroprotective strategies for different neurodegenerative diseases, whereas 
the use of ERα ligands should be restricted due to side effects in the womb and uterus (176). 
In contrast, other studies reported neuroprotection mediated by the ERα through signaling 
mechanisms mediated exclusively by astrocytes (177).  
 
In addition to estrogenic compounds, progestogens and androgens have been studied in 
animal models for neurodegenerative diseases showing their neuroprotective potential. In the 
case of progestogens, it has been reported that their synthesis can be induced by estradiol in 
astrocytes (178), suggesting not only the importance of estradiol on progesterone synthesis, 
but also their combined action with other steroids. The progestogenic activity of tibolone is of 
great interest given that protective effects mediated by progesterone (pre- and post-insult) 
have been reported in different models that mimic the physiopathological conditions of 
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glucose deprivation, among others (179). In the CNS, different brain areas such as the 
hippocampus, cerebral cortex, spinal cord and sciatic nerve exhibit this protective effect of 
tibolone (180) (Table 1). 
 
Interestingly, tibolone’s actions in the brain are partly mediated by ERβ. Tibolone has been 
shown to induce protective effects in both microglia and astroglial cells upon different 
inflammatoty stimuli (23, 24, 29-32). For example, astrocytic cells exposed to glucose 
deprivation present more fragmented nuclei and increased levels of oxidative stress. 
Treatment of cells with tibolone (10nM) or DPN (an ERβ agonist) but not with PPT (an ERα 
agonist) preserved mitochondrial function and improved the outcome in a similar fashion 
(24), suggesting an estrogenic action of tibolone in astrocytes. However, after blocking ERβ 
using an antagonist, protection with tibolone in astrocytic cells deprived of glucose is 
dampened and more cell death is observed (24). Similarly, in BV-2 microglial cells exposed 
to lipotoxicity with palmitic acid, cells treated with tibolone are rescued by a mechanism that 
involves ERβ and neuroglobin. In this regard, several studies have shown that neuroglobin 
expression is increased in both astrocytes and microglial cells after treatment with estradiol, 
testosterone and tibolone, suggesting that this protein is hormonally regulated. Blocking the 
expression of neuroglobin using siRNA reduced the protective effects of tibolone in 
microglia and astrocytes subjected to metabolic dysfunction (24, 32). It has also been shown 
that tibolone induces protection in glial cells by epigenetic mechanisms, and these include the 
regulation of interleukin-6, miRNA, TERT, DNA methylation and telomeric complex  (29, 
30).   
 
6. Conclusions 
The excess of free saturated FAs in the circulation has direct effects on the homeostasis and 
functioning of the CNS. Free saturated FAs have consequences on different cells of the brain 
and their compartments. The main effects are evidenced at the mitochondrial level where an 
increase in oxidative stress contributes to the activation of inflammatory mechanisms that 
could lead to cell death. In the last decade and as shown in this review, treatment with 
neuroactive steroids has been of great interest due to the fundamental protective role that they 
have on the CNS. Neuroactive steroids can be characterized by their antioxidant and 
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effects on the survival and modulation of astrocytes and microglia are both dependent on and 
independent of the estrogen receptors, which trigger the activation of signaling pathways and 
transcription factors of genes involved in the inflammatory response and cell protection. 
Therefore, neuroactive steroids, such as tibolone and estradiol, are promising therapeutic 
candidates for the treatment of pathologies that affect the CNS to attenuate the progression of 
diseases related to exacerbated inflammatory processes. Future clinical studies on the use of 
steroids in the CNS diseases are warranted. 
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Table 1. Studies on the relationship between fatty acid and estrogen in the brain. 
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Figure 1.  Fatty acids induce inflammation in the nervous system and attenuate the 
signaling pathway of insulin in obesity. The excess of fatty acids produce inflammation 
principally by means of three mechanisms. a) Increase in lipotoxicity when the FA 
concentration exceeds the oxidative requirements, increasing the levels of diacylglycerol 
(DAG) and ceramide. DAG activates protein kinase C (PKC) that activates the nuclear 
factor inhibitor NF-kB (IkB) kinase (IKKβ-NF-kB) pathway, causing inflammation. A high 
concentration of ceramides activates the nodule-type receptor that contains a pirine domain 
(NLRP3), modulating the release of interleukin (IL)-1β and also leads to the activation of 
the protein phosphatase 2A (PP2A), attenuating the signaling pathway of insulin. b) 
Palmitic acid dysregulates the function of the endoplasmic reticulum (ER) producing stress 
and inflammation via NF-kB, N-terminal c-Jun (JNK) and NLRP3 inflammasome, leading 
to further generation of reactive oxygen species (ROS) in mitochondria. c) Palmitic acid 
activates the toll-like receptor (TLR)-4 through fetuin A; likewise high-fat diets increase 
lipopolysaccharide levels (LPS), an activator of this receptor, which leads to an increase in 
the activity of the IKKβ-NF-kB pathway. 
 
Figure 2.   Effect of fatty acids (FA) on the central nervous system. Metabolic diseases 
such as obesity are characterized by the accumulation of multiple metabolites that generate 
alterations on physiological conditions. The excess of fatty acids can contribute to an 
increase in inflammatory processes directly affecting the brain. The increase in the BBB 
permeability facilitates the entry of FA and subsequent recognition by brain cells (neurons, 
astrocytes, microglia), triggering different response mechanisms that contribute to the 
appearance of a neuroinflammatory environment, characterized by secretion of 
inflammatory cytokines, the activation of glial cells and neuronal death among others. The 
activation of microglia implies morphological and functional changes from a chronic 
inflammation, whereby through signaling pathways and transcription factors related to 
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Figure 3.  Neurosteroids and neuroactive steroids have protective effects on the CNS cells. 
Treatment with estradiol, SERMs and STEARs has protective effects on the integrity of the 
cerebral microenvironment. Different investigations have reported that these molecules 
recover mitochondrial functions, oxidative stress, reduce the release of inflammatory 
factors (chemokines, cytokines, etc.) and attenuate the expression of proinflammatory and 
pro-apoptotic proteins and genes. This protection is due to the activation of estrogen 
receptors and GPER, among others, where through genomic and non-genomic mechanisms 
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